- Home
- STEM vs INKT Comparison
STEM vs INKT Comparison
Compare STEM & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STEM | INKT |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 70.6M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STEM | INKT |
|---|---|---|
| Price | $7.46 | $12.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $13.33 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 151.4K | 38.0K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | N/A |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $14.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $6.04 | $6.80 |
| 52 Week High | $32.23 | $76.00 |
Technical Indicators
Market Signals| Indicator | STEM | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 37.90 | 52.49 |
| Support Level | $7.20 | $10.82 |
| Resistance Level | $10.96 | $12.45 |
| Average True Range (ATR) | 0.63 | 0.83 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 10.57 | 45.36 |
Price Performance
Historical ComparisonAbout STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.